In both cases, we are confident that the additional efforts we are undertaking would be more than compensated for by the times we should be able to achieve upon licensing the candidates, assuming of course continuing development success. Therefore, as the final piece of infrastructure required with regard to implementing our strategy for our current areas of focus, we were extremely pleased that Mary, a world recognized expert in the monoclonal antibody field agreed to take the lead in establishing a monoclonal antibody development capabilities for us here at Compugen Inc in South San Francisco.Read the rest of this transcript for free on seekingalpha.com
Compugen's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.